arrow
Y

Yutaka Fujiwara

Aichi Cancer Center Hospital
H指数:42
被引数:6,707

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real‐World Progression Patterns and Potential Prognostic Factors for Trastuzumab Deruxtecan‐Related Interstitial Lung Disease in Japanese Patients With Breast or Gastric Cancer

日本乳腺癌或胃癌患者中曲妥珠单抗德鲁替康相关间质性肺病的真实世界进展模式及潜在预后因素

2026-11-090
OAAI
Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer

日本乳腺癌和胃癌患者中曲妥珠单抗德鲁克替康相关间质性肺疾病的真实世界特征

2026-09-070
OAAI
Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC

奥罗莫西布与帕博利珠单抗联合治疗KRAS G12C突变型晚期非小细胞肺癌的疗效与安全性

2025-11-290
PRE
Phase III study of zipalertinib plus fi rst-line (1L) platinum- based chemotherapy in patients (pts) with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (ex20ins) mutations (REZILIENT3): Safety lead-in results

三代研究:泽帕拉替尼联合一线(1L)铂类为基础的化疗,用于携带EGFR外显子20插入(ex20ins)突变的患者(pts)的非小细胞肺癌(NSCLC)治疗(REZILIENT3):安全性导入期结果

2024-12-010
PRE
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial
2024-11-011
PRE
The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review

非小细胞肺癌患者在有无血管内皮生长因子抑制剂的情况下,表皮生长因子受体酪氨酸激酶抑制剂或免疫检查点抑制剂引起的药物性间质性肺疾病的发生率: 系统评价

2024-06-111
OAAI
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan (vol 28, pg 1585, 2023)

癌症患者接受曲妥珠单抗德鲁克替康治疗后间质性肺病的临床及影像学特征(卷28,页1585,2023)

2023-10-280
OA
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)

epacadostat单独或与pembrolizumab联合治疗晚期实体瘤患者的安全性和耐受性: 日本首次I期研究的结果 (KEYNOTE-434)

2020-06-207
PREAI